The global nuclear medicine or radiopharmaceuticals market is projected to reach USD 9,520 million by 2028, with a CAGR of 7.6% from 2021 to 2028. This growth is driven by factors such as the increasing prevalence of cancer, advancements in imaging technology, and the growing geriatric population. Nuclear medicine involves the use of radioactive substances for diagnostic and therapeutic purposes, particularly in cancer treatment. Diagnostic procedures use radiotracers, which emit gamma rays that are detected by a camera and computer to generate internal images of the body. Radiopharmaceuticals containing radioisotopes can be administered as medicinal solutions to destroy cancer cells by emitting radiation. The market presents opportunities in areas such as targeted therapy for cancer, the development of novel radiotracers, and the adoption of hybrid imaging systems. The report includes a major chapter on the customized report and segments the market based on type, modality, application, and end user. The regional outlook includes North America, Eastern Europe, Western Europe, Asia Pacific, Middle East & Africa, and South America.
Sat, 08 Jul 2023 08:49:04 GMT | Digital Journal